Results 161 to 170 of about 7,099 (210)

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. [PDF]

Clin Infect Dis
Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team.   +28 more
europepmc   +1 more source

Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis. [PDF]

Sci Rep
Taguchi N, Piao Y, Rubino A, Lee K, Chen M, Harada K, Tanikawa T, Naito T.   +7 more
europepmc   +1 more source

P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate

Journal of the International AIDS Society, 2015
Edwin DeJesus, Paul Sax, Michael Yin, Frank Post, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade-Villanueva, Huyen Cao, Julie Ryu, Marshall Fordyce   +10 more
openaire   +1 more source

Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques. [PDF]

J Infect Dis
Makarova N, Singletary T, Peet MM, Mitchell J, Bachman S, Holder A, Dinh C, Lipscomb J, Agrahari V, Mendoza M, Pan Y, Heneine W, Clark MR, García-Lerma JG, Doncel GF, Smith JM.   +15 more
europepmc   +1 more source

Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. [PDF]

Pathogens
Fülöp B, Fischer J, Hahn M, Böhlig A, Matz-Soja M, Berg T, van Bömmel F.   +6 more
europepmc   +1 more source

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A.   +5 more
europepmc   +1 more source

Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate: Systematic Review and Meta-Analysis [PDF]

International Journal of Pulmonary & Respiratory Sciences, 2018
openaire   +1 more source

Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A.   +5 more
europepmc   +1 more source

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. [PDF]

PLoS One
Lee SY, Lin YC, Chen CP, Cheng SH, Chang SY, Ku SY, Cheng CY.   +6 more
europepmc   +1 more source

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. [PDF]

AIDS
Moore AEB, Burns JE, Sally D, Milinkovic A, Krokos G, John J, Rookyard C, Borca A, Pool ERM, Tostevin A, Harman A, Dulnoan DS, Gilson R, Arenas-Pinto A, Cook GJR, Saunders J, Saunders J, Dunn D, Blake GM, Pett SL.   +19 more
europepmc   +1 more source